HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study for its investigational compound HMPL-506 in China, with the first patient having already been dosed. The molecule is being evaluated as a potential treatment for various hematologic malignancies.
This multi-center, open-label Phase I study is designed to evaluate the safety, pharmacokinetics, and efficacy of HMPL-506 in patients with hematologic malignancies. The trial includes both dose-escalation and dose-expansion phases and is anticipated to enroll a minimum of 60 patients.
HMPL-506 is an orally administered small-molecule inhibitor of Menin protein, which acts as a scaffold protein influencing gene expression and cellular signaling pathways. The compound is of particular interest due to its potential role in treating acute myeloid leukemia (AML) with mixed lineage leukemia (MLL, also known as KMT2A) rearrangement and/or nuclear phosphoprotein 1 (NPM1) mutation. Approximately 5% of adult AML cases feature MLL rearrangement, and around 30% have NPM1 mutations. Current research indicates that inhibiting menin-MLL interactions could be a promising therapeutic strategy for these patient populations. To date, no menin inhibitor has been approved worldwide, and HutchMed retains all global rights to HMPL-506.- Flcube.com
